SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing extreme volatility and trending due to a massive short squeeze, with the stock price surging dramatically this week. The community is actively discussing potential price targets, expressing both excitement and disbelief at the rapid gains, and debating whether the surge is sustainable or a potential bubble. Some traders are drawing comparisons to other high-flying stocks and are looking for similar opportunities.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation of acquiring Warner Bros. Discovery, with discussions centering on the potential benefits of consolidating content libraries and HBO's subscriber base. However, the community is also weighing potential regulatory hurdles, debt implications, and the impact on market competition, with some viewing the deal as an overreach.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition, with Netflix reportedly submitting a mostly cash bid, fueling a bidding war against Paramount and Comcast. Community chatter revolves around potential deal structures, regulatory hurdles, and whether a higher bid will emerge. Some traders speculate on potential outcomes for shareholders depending on the final deal.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TREASURE GLOBAL INC ($TGL) is trending due to its recent volatility and discussions around a potential short squeeze, driven by a low float and high borrowing fees. The community is actively debating the impact of a possible reverse stock split and monitoring for news related to AI initiatives and partnerships that could drive the price higher. Comparisons to previous runners like $SMX are common, with some anticipating a similar explosive move.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders weigh the possibility of a December rate cut by the Federal Reserve amid mixed signals and a recent government shutdown impacting economic data releases. Community members are actively discussing potential safe-haven assets and the impact of a 50-year mortgage proposal, with some anticipating a bond market rally while others remain bearish. The conversation also encompasses concerns about debt, economic strength, and shifting global dynamics influencing the long-term treasury bond ETF.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending as traders discuss its potential for a short squeeze, drawing comparisons to other recent low float runners like $SMX. The community is actively debating its low float and high short interest, while acknowledging the stock's history of volatility and reverse splits. Some are also noting the company's assets relative to its market cap.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices have recently seen significant volatility, driven by weather forecasts and fluctuating LNG exports. Community discussions revolve around whether a sustained rally is in store or if a pullback is imminent, considering high storage levels and production. Traders are actively debating potential entry points, technical indicators, and the impact of upcoming contract rollovers.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chun Sing Chan on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a combination of strong revenue growth news and speculation of a potential short squeeze, fueled by its low float. The community is actively comparing it to other Hong Kong-based stocks known for parabolic runs, while also discussing the company's shift towards AI-driven solutions and government contracts. High insider ownership is seen as a positive, though some traders are wary of the stock's volatile history.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe ($ADBE) is trending as investors debate its valuation and future amid AI competition, with some viewing it as undervalued while others express frustration with its performance. Discussions revolve around potential catalysts like upcoming earnings and possible acquisitions, as well as concerns about management and market sentiment. Many are closely watching key support levels, anticipating a potential rebound or further downside.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors digest recent earnings, upgrades from analysts, and a strategic partnership with AWS, with community members debating whether the stock is undervalued and poised for long-term growth. The focus remains on the company's position in cybersecurity and data resilience, along with its potential in AI. Some traders are taking profits, while others see the dip as a buying opportunity, expressing conviction in Rubrik's future and its role in protecting data amid rising cyber threats.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q32 Bio (NASDAQ:QTTB) CFO Lee Kalowski Sells 9,072 Shares

Q32 Bio Inc. (NASDAQ:QTTB - Get Free Report) CFO Lee Kalowski sold 9,072 shares of the business's stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $3.46...

Best Biotech Stocks To Research - December 1st

Q32 Bio, Cidara Therapeutics, Danaher, argenex, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Medical Stocks To Research - December 1st

Eli Lilly and Company, UnitedHealth Group, Pfizer, Q32 Bio, and Johnson & Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares...

<ul class="summary-bullets"><li>ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.</li><li>Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.</li><li>The company is now focussed on advancing Bempikibart for patients with alopecia areata.</li></ul> Shares of Q32 Bio Inc. (QTTB) jumped 98% on Monday after the company sold its experimental drug ADX-097, to Akebia Therapeutics, Inc. (AKBA) for up to $592 million.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.q32bio.com/news-releases/news-release-details/q32-bio-sells-complement-inhibitor-adx-097">said</a> that the sale extends its cash runway into the second half of 2027. ADX-097 is designed to inhibit complement activation, an integral part of the innate immune system, and has potential across kidney, autoimmune, vascular and skin diseases.<h2 class="st-heading-2">Terms Of The Deal</h2>Akebia will now be responsible for future development and commercialization of ADX-097. Under the deal, Q32 Bio will receive $12 million in upfront payments and near-term milestone payments.These payments as well as potential development, regulatory and commercial milestones total up to $592 million, the company said. Q32 Bio is also eligible to receive tiered royalties on potential future sales of ADX-097, ranging from low single-digit to mid-teen percentages.ADX-097 is the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform. Q32 Bio, however, retains the rights to the platform, including ADX-096 being developed for ophthalmologic indications and other remaining early-stage assets and is continuing to evaluate strategic options for these programs.The company is now focussed on advancing Bempikibart for patients with alopecia areata, an autoimmune disorder that causes the immune system to attack hair follicles, resulting in sudden, patchy hair loss, most commonly on the scalp.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QTTB">QTTB stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Nov. 28, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>QTTB’s Sentiment Meter and Message Volume as of 12:40 p.m. ET on Dec. 1, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the deal opening opportunities for the company.<stembedurl>https://stocktwits.com/topstockalerts/message/637812919</stembedurl>QTTB stock is up by 26% this year but down by about 84% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/connecticut-attorney-general-presses-bnpl-firms-paypal-sezzle-on-fees-disclosure-debt-risks/cLI71TxREiD">Connecticut Attorney General Presses BNPL Firms PayPal, Sezzle On Fees, Disclosures And Debt Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M

The company said that the sale extends its cash runway into the second half of 2027.

Equity

The company said that the sale extends its cash runway into the second half of 2027.


<ul class="summary-bullets"><li>Moderna shares were down around 6% in Monday’s midday trade after the U.S. Food and Drug Administration outlined stricter vaccine approval rules in an internal memo last week.</li><li>Strategy shares were down more than 11% in Monday’s midday session after Bitcoin prices fell below $84,000.</li><li>Q32 Bio shares were up more than 100% in Monday’s midday trade after the company announced the sale of its Phase 2 complement inhibitor to Akebia Therapeutics.</li></ul>U.S. equities were down in Monday’s midday trade, beginning December on a negative note, even as Wall Street keeps an eye out for commentary from Federal Reserve Chair Jerome Powell later in the day.Tom Lee, Managing Partner at Fundstrat Global Advisors, on Monday laid out his&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fundstrat-tom-lee-sp-500-prediction-climb-7300-in-december/cLI7gvmREiN">bull thesis</a> for the S&amp;P 500 heading into the year-end, listing seasonal tailwinds and a boost to equities from the Fed’s monetary policy decision as the two reasons behind his optimism.“I think the biggest tailwind that’s going to emerge in the next couple of weeks is around the central bank. The Fed is set to cut in December,” Lee said.According to data from the CME FedWatch&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, the probability of a 25-basis-point rate cut in December has increased to 87.6%, up from 84.4% a week ago.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.28% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, fell 0.34%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.42%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s midday trade:</h2><a href="https://stocktwits.com/symbol/SNPS">Synopsys Inc. (SNPS)</a>Synopsys shares were up nearly 4% in Monday’s midday session after AI bellwether Nvidia Corp. (NVDA)&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/synopsys-pops-after-nvidia-takes-2-billion-stake/cLI7XITREij">announced</a> a $2 billion investment in the company. As part of the partnership, Nvidia’s AI capabilities will be paired with Synopsys’ engineering software to help in designing, simulating, and verifying products faster.<a href="https://stocktwits.com/symbol/SNPS">SNPS stock</a> is down 11% year-to-date.<a href="https://stocktwits.com/symbol/MRNA">Moderna Inc. (MRNA)</a>Moderna shares were down around 6% in Monday’s midday trade after the U.S. Food and Drug Administration (FDA) outlined stricter vaccine approval rules in an internal memo last week, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.barrons.com/articles/moderna-and-novavax-stocks-drop-as-fda-proposes-stricter-vaccine-approvals-beba1a96">report</a> by Barron’s. Novavax Inc. (NVAX) and BioNTech SE’s (BNTX) shares were down 4% each.<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> is down 42% year to date.<a href="https://stocktwits.com/symbol/MSTR">Strategy Inc. (MSTR)</a>Strategy shares were down more than 11% in Monday’s midday session after Bitcoin (BTC) prices fell below $84,000. At the time of writing, Bitcoin was down nearly 8% over the past 24 hours. The decline in Bitcoin prices triggered nearly $1 billion in&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-to-84000-1-billion-wiped-out-mstr-bmnr-lead-crypto-stocks-selloff/cLI71d2REix">liquidations</a> in the last 24 hours.<a href="https://stocktwits.com/symbol/MSTR">MSTR stock</a> is down 45% year to date.<a href="https://stocktwits.com/symbol/QTTB">Q32 Bio Inc. (QTTB)</a>Q32 Bio shares were up more than 100% in Monday’s midday trade after the company announced the sale of its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA). As part of the deal, Q32 is eligible to receive up to $592 million upon achievement of certain milestones, including $12 million upfront.<a href="https://stocktwits.com/symbol/QTTB">QTTB stock</a> is up 27% year-to-date.<a href="https://stocktwits.com/symbol/WOLF">Wolfspeed Inc. (WOLF)</a>Wolfspeed shares were up around 8% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-wolfspeed-stock-rise-7-today/cLI7K6PREiw">announced</a> the receipt of $698.6 million in cash tax refunds from the Internal Revenue Service (IRS).<a href="https://stocktwits.com/symbol/WOLF">WOLF stock</a> is up 21% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-cuts-zepbound-weight-loss-drug-prices-to-299-a-month/cLI7QykREih">Eli Lilly Cuts Prices For Weight Loss Drug Zepbound To $299 A Month As It Takes On Novo Nordisk’s Wegovy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today

Synopsys shares were up nearly 4% in Monday’s midday session after AI bellwether Nvidia announced a $2 billion investment in the company.

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio shares rise after selling ADX-097 to Akebia in a deal worth up to $592 million, boosting cash runway into late 2027.read more...

Q32 Bio Sells Complement Inhibitor ADX-097

Q32 Bio Sells Complement Inhibitor ADX-097 Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire WALTHAM, Mass., Dec. 1, 2025 -- Asset sale further enables Company's strategic focus on advancing...

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov...

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a...

Retail investor interest in Q32 Bio Inc picked up on Wednesday after the clinical-stage biotech said the U.S. Food and Drug Administration granted Fast Track designation to its experimental treatment for alopecia areata.The drug, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody being tested in a Phase 2 trial for alopecia areata (AA), an autoimmune disorder that causes hair loss.&nbsp;The Fast Track status is intended to speed development of therapies that address serious conditions and unmet medical needs."The Fast Track designation granted by the FDA recognizes the seriousness of AA and the significant current unmet medical need while underscoring bempikibart's potential as a novel, differentiated therapy," said Q32 Bio Chief Executive Jodie Morrison in a statement.Bempikibart is designed to re-regulate immune function by blocking IL-7 and TSLP signaling pathways, key components in autoimmune activity.&nbsp;The company recently began dosing patients in both an open-label extension and Part B of its SIGNAL-AA trial following encouraging early results.The FDA designation allows for more frequent meetings with the agency, eligibility for priority review, and the possibility of accelerated approval, subject to clinical results.On Stocktwits, 24-hour message volume for Regulus jumped by 1,600% amid bullish sentiment.Some users highlighted the stock’s low float and recent FDA news as drivers for a potential swing trade, while others noted that the therapy itself — bempikibart — is making steady clinical progress.&nbsp;<stembedurl>https://stocktwits.com/onlyfactshere/message/613083538</stembedurl>One user pointed to the Fast Track status as a key catalyst, potentially accelerating development timelines for a treatment area with few approved options.&nbsp;<stembedurl>https://stocktwits.com/ALOSETE/message/613089756</stembedurl>Still, some cautioned that despite promising Phase 2 data, the company’s limited cash runway — estimated at about five quarters — underscores the inherent risks of biotech investing.<stembedurl>https://stocktwits.com/Rage_Against_The_Machine/message/613078123</stembedurl>Shares of Q32 Bio have declined 1.9% year-to-date, underperforming the Nasdaq, which is down 1.6%, but faring better than the Dow and S&amp;P 500, which have fallen 4.1% and 5.1%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Q32 Bio Stock Turns Retail Trader Heads After FDA Grants Fast Track For Alopecia Drug

Q32 Bio shares drew renewed attention on Wednesday after the FDA granted Fast Track designation to its experimental alopecia areata treatment, bempikibart. The designation could accelerate development and review of the Phase 2-stage therapy.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

Current Price	$3.38
Prev Close	$3.62
Open	$3.60
Dividend Yield	0.00%
50-Day Moving Average	$2.64
Beta	0.65
Avg. Volume	70,724.42
PE Ratio	-1.05

52-Week High	$28.06
52-Week Low	$1.35
Market Capitalization	$44.54M
EPS (Annual)	-$6.58
Price to Book	-2.41
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

QTTB
Q32 Bio Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest QTTB News

QTTBQ32 Bio Inc.